Drug intelligence / Profile preview

Fenoxazoline

Development stage: Unknown
Modality: Small Molecules
Administration: Topical, Intranasal

Overview

Fenoxazoline is a small molecule nasal decongestant used primarily for the relief of nasal congestion. It acts as a sympathomimetic agent by mimicking the effects of the sympathetic nervous system to constrict blood vessels in the nasal passages and reduce swelling. The drug is typically administered topically as a nasal solution. Its mechanism of action involves vasoconstriction through stimulation of alpha-adrenergic receptors in the nasal mucosa. Fenoxazoline has been marketed under various trade names including Aturgyl (in Brazil), Nasofelin, Nebulicina, Rhinox, Nasenol, and Nasostop. It has reached up to phase II clinical trials for at least one investigational indication.

Brand names: AturgylNasofelinNebulicinaRhinoxNasenolNasostop
Other names: FenossazolinaFenoxazolina

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on Fenoxazoline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fenoxazoline.

Explore the full profile